GNA NOW logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 16
Grant agreement number
853979

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
12 299 995
EFPIA in kind
19 115 992
Total Cost
31 415 987

Summary

Antimicrobial resistance (AMR) is a major threat to public health, causing 670 000 infections and over 33 000 deaths in Europe alone in 2015. So-called Gram-negative bacteria are particularly tough to treat, as they are encased in a tough outer membrane which effectively stops many antibiotics from getting into the bacteria and killing it. The GNA NOW project aims to address the urgent need for new antibiotics to treat Gram-negative infections by attacking the bacteria in new and different ways. The team will run three programmes in parallel, each focusing on a different drug candidate with an innovative mode of action. All drug candidates will undergo a range of tests to ensure their safety and efficacy and to understand and optimise how they work. The project hopes to complete phase 1 clinical trials for at least one candidate, and advance at least one more to the stage where it is ready to enter clinical trials.

GNA NOW is part of the IMI AMR Accelerator Programme.

Participants Show participants on map

EFPIA companies
  • Evotec International GMBH, Hamburg, Germany
Universities, research organisations, public bodies, non-profit groups
  • Bioaster Fondation De Cooperation Scientifique, Lyon, France
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Medizinische Universitaet Wien, Vienna, Austria
  • North Bristol National Health Service Trust, Bristol, United Kingdom
  • The University Of Liverpool, Liverpool, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Nosopharm, Nimes, France
  • Stichting Lygature, Utrecht, Netherlands
Third parties
  • Universite De Poitiers, Poitiers , France

CONTACT

Project coordinator
Kristina Orrling
STICHTING LYGATURE
kristina.orrling[at]lygature.org